Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) shares were up 7.8% during mid-day trading on Wednesday . The company traded as high as $0.20 and last traded at $0.19. Approximately 19,100 shares traded hands during trading, a decline of 88% from the average daily volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Stock Up 7.8 %
The business’s 50-day simple moving average is $0.19 and its 200-day simple moving average is $0.19. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.04.
Vyant Bio Company Profile
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Further Reading
- Five stocks we like better than Vyant Bio
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
- NYSE Stocks Give Investors a Variety of Quality Options
- Power Play: Japan’s Top Auto Stocks Eye Historic Merger
- Differences Between Momentum Investing and Long Term Investing
- S&P 500 Earnings Set to Shine: January’s Critical Market Test
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
